Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS

@article{Wolfson2012LucinactantAP,
  title={Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS},
  author={Marla R. Wolfson and J Wu and Terrence L. Hubert and Timothy J D Gregory and Jan L Mazela and Thomas H Shaffer},
  journal={Pediatric Research},
  year={2012},
  volume={72},
  pages={375-383}
}
Background:Acute inflammatory responses to supplemental oxygen and mechanical ventilation have been implicated in the pathophysiological sequelae of respiratory distress syndrome (RDS). Although surfactant replacement therapy (SRT) has contributed to lung stability, the effect on lung inflammation is inconclusive. Lucinactant contains sinapultide (KL4), a novel synthetic peptide that functionally mimics surfactant protein B, a protein with anti-inflammatory properties. We tested the hypothesis… CONTINUE READING
Highly Cited
This paper has 20 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Reintubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy

CG Guardia, FR Moya, S Sinha
J Neonatal Perinatal Med • 2011

Surfactant proteind inhibits lung inflammation caused by ventilation in premature newborn lambs

A Hilgendorff, K Parai, R Ertsey
Am J Respir Crit Care Med • 2010

Similar Papers

Loading similar papers…